12
Participants
Start Date
January 31, 2009
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
eltrombopag
Eltrombopag, administered orally, 50 mg/daily for 21 days. Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days. Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days. Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.
Fondazione IRCCS Policlinico San Matteo, Unità di Medicina III, Pavia
Azienda Ospedaliero-Universitaria di Padova, Unità di Medicina Generale e Patologia Speciale, Padua
Policlinico Monteluce, Sezione di Medicina Interna e Cardiovascolare, Perugia
Collaborators (1)
University of Pavia
OTHER
GlaxoSmithKline
INDUSTRY
Azienda Ospedaliera di Padova
OTHER
Azienda Ospedaliera di Perugia
OTHER
Fondazione Telethon
OTHER
Fondazione IRCCS Policlinico San Matteo di Pavia
OTHER